Specialization for Cell-Free or Cell-to-Cell Spread of BAC-Cloned Human Cytomegalovirus Strains Is Determined by Factors beyond the UL128-131 and RL13 Loci.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
16 06 2020
Historique:
received: 07 01 2020
accepted: 13 04 2020
pubmed: 24 4 2020
medline: 18 12 2020
entrez: 24 4 2020
Statut: epublish

Résumé

It is widely held that clinical isolates of human cytomegalovirus (HCMV) are highly cell associated, and mutations affecting the UL128-131 and RL13 loci that arise in culture lead to the appearance of a cell-free spread phenotype. The bacterial artificial chromosome (BAC) clone Merlin (ME) expresses abundant UL128-131, is RL13 impaired, and produces low infectivity virions in fibroblasts, whereas TB40/e (TB) and TR are low in UL128-131, are RL13 intact, and produce virions of much higher infectivity. Despite these differences, quantification of spread by flow cytometry revealed remarkably similar spread efficiencies in fibroblasts. In epithelial cells, ME spread more efficiently, consistent with robust UL128-131 expression. Strikingly, ME spread far better than did TB or TR in the presence of neutralizing antibodies on both cell types, indicating that ME is not simply deficient at cell-free spread but is particularly efficient at cell-to-cell spread, whereas TB and TR cell-to-cell spread is poor. Sonically disrupted ME-infected cells contained scant infectivity, suggesting that the efficient cell-to-cell spread mechanism of ME depends on features of the intact cells such as junctions or intracellular trafficking processes. Even when UL128-131 was transcriptionally repressed, cell-to-cell spread of ME was still more efficient than that of TB or TR. Moreover, RL13 expression comparably reduced both cell-free and cell-to-cell spread of all three strains, suggesting that it acts at a stage of assembly and/or egress common to both routes of spread. Thus, HCMV strains can be highly specialized for either for cell-free or cell-to-cell spread, and these phenotypes are determined by factors beyond the UL128-131 or RL13 loci.

Identifiants

pubmed: 32321807
pii: JVI.00034-20
doi: 10.1128/JVI.00034-20
pmc: PMC7307150
pii:
doi:

Substances chimiques

Membrane Glycoproteins 0
Membrane Proteins 0
RL13 protein, human cytomegalovirus 0
UL128 protein, human cytomegalovirus 0
Viral Envelope Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI097274
Pays : United States

Informations de copyright

Copyright © 2020 American Society for Microbiology.

Références

J Gen Virol. 2016 Aug;97(8):1917-1927
pubmed: 27050420
J Gen Virol. 2008 Feb;89(Pt 2):359-368
pubmed: 18198366
J Virol. 2007 Aug;81(15):7825-32
pubmed: 17459936
J Virol. 2005 Aug;79(16):10330-8
pubmed: 16051825
J Virol. 2018 Oct 12;92(21):
pubmed: 30111564
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Virology. 1996 Feb 1;216(1):133-45
pubmed: 8614980
Int J Mol Sci. 2019 Jun 28;20(13):
pubmed: 31261659
J Clin Virol. 2006 Sep;37(1):10-20
pubmed: 16815742
J Virol. 1989 Mar;63(3):1345-53
pubmed: 2536837
J Virol. 2002 Nov;76(21):10841-8
pubmed: 12368327
Methods Mol Biol. 2015;1241:23-38
pubmed: 25308485
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6104-6109
pubmed: 28533400
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
J Virol. 2019 Jan 17;93(3):
pubmed: 30404805
Arch Virol. 1992;126(1-4):67-80
pubmed: 1326269
J Virol. 2015 May 13;89(15):7673-7695
pubmed: 25972543
Virus Evol. 2016 Jun 15;2(1):vew017
pubmed: 30288299
J Virol. 2017 Jun 9;91(13):
pubmed: 28381568
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7043-7052
pubmed: 30894498
J Virol. 2006 Jan;80(2):710-22
pubmed: 16378974
J Virol. 2013 Sep;87(17):9680-90
pubmed: 23804643
PLoS Pathog. 2015 Feb 06;11(2):e1004640
pubmed: 25659098
J Virol. 2015 Dec 09;90(5):2294-305
pubmed: 26656708
Curr Opin Organ Transplant. 2018 Aug;23(4):388-394
pubmed: 29794552
J Virol. 2008 Jan;82(1):60-70
pubmed: 17942555
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
J Virol. 2020 Mar 31;94(8):
pubmed: 31996433
J Gen Virol. 2004 May;85(Pt 5):1301-1312
pubmed: 15105547
PLoS Pathog. 2017 Apr 12;13(4):e1006273
pubmed: 28403220
J Gen Virol. 2006 Sep;87(Pt 9):2451-60
pubmed: 16894182
J Clin Microbiol. 2002 Jan;40(1):233-8
pubmed: 11773121
J Infect Dis. 2019 Jul 31;220(5):781-791
pubmed: 31050742
J Clin Virol. 2018 Nov;108:132-140
pubmed: 30312910
J Clin Invest. 2010 Sep;120(9):3191-208
pubmed: 20679731
J Virol. 2013 Oct;87(19):10489-500
pubmed: 23885075
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9889-E9898
pubmed: 30275317
PLoS Pathog. 2016 Apr 15;12(4):e1005564
pubmed: 27082872
J Virol. 2008 Oct;82(20):9994-10007
pubmed: 18684829
J Virol. 2008 Dec;82(23):11837-50
pubmed: 18815310
Science. 2008 Jun 13;320(5882):1496-501
pubmed: 18497260
Nat Microbiol. 2016 Jun 06;1(8):16082
pubmed: 27573107
PLoS Pathog. 2011 May;7(5):e1001344
pubmed: 21625576
PLoS One. 2015 Aug 12;10(8):e0135567
pubmed: 26267274
J Virol. 2010 Mar;84(5):2585-96
pubmed: 20032184
Viruses. 2019 Mar 05;11(3):
pubmed: 30841507
J Virol. 2016 Jun 24;90(14):6216-6223
pubmed: 27122579
J Gen Virol. 1999 Nov;80 ( Pt 11):2867-2877
pubmed: 10580048
PLoS Pathog. 2013;9(7):e1003463
pubmed: 23853586
J Virol. 2000 Jun;74(12):5629-38
pubmed: 10823870
N Engl J Med. 1983 Apr 21;308(16):921-5
pubmed: 6300675
J Gen Virol. 2010 Jun;91(Pt 6):1535-46
pubmed: 20479471
Cell. 2018 Aug 23;174(5):1158-1171.e19
pubmed: 30057110
J Infect Dis. 2019 Jul 31;220(5):792-801
pubmed: 31050737
J Virol. 1997 Jul;71(7):5391-8
pubmed: 9188610
J Virol. 1997 Apr;71(4):3090-7
pubmed: 9060671
Antimicrob Agents Chemother. 1998 Feb;42(2):444-6
pubmed: 9527804
J Virol. 2008 Mar;82(6):2802-12
pubmed: 18184717
Vaccine. 2011 Mar 24;29(15):2705-11
pubmed: 21310190
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5693-5698
pubmed: 30819890
PLoS Pathog. 2011 Jan 13;7(1):e1001256
pubmed: 21249233
J Virol. 2018 Jul 17;92(15):
pubmed: 29743375
J Virol. 2004 Sep;78(18):10023-33
pubmed: 15331735
PLoS Genet. 2013;9(9):e1003735
pubmed: 24086142
J Virol. 2015 Sep;89(17):8999-9009
pubmed: 26085146
Rev Med Virol. 2011 Jul;21(4):240-55
pubmed: 21674676
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2081-6
pubmed: 15684067
Science. 2012 Nov 23;338(6110):1088-93
pubmed: 23180859
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81
pubmed: 14657367
J Gen Virol. 2016 Sep;97(9):2376-2386
pubmed: 27405754
Nat Rev Microbiol. 2011 May;9(5):369-81
pubmed: 21478902
PLoS One. 2012;7(11):e50166
pubmed: 23226246
J Virol. 2016 Mar 28;90(8):3929-43
pubmed: 26842472
Virology. 2013 Jun 20;441(1):75-84
pubmed: 23562482
PLoS Pathog. 2013;9(7):e1003493
pubmed: 23935483
J Med Virol. 2005 Jan;75(1):42-6
pubmed: 15543586
Exp Hematol. 2003 Nov;31(11):1007-14
pubmed: 14585362
Virology. 2004 Jan 20;318(2):582-97
pubmed: 14972526
PLoS Pathog. 2017 Apr 12;13(4):e1006281
pubmed: 28403202

Auteurs

Eric P Schultz (EP)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA.
Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, Montana, USA.

Jean-Marc Lanchy (JM)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA.

Le Zhang Day (LZ)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA.
Biochemistry and Biophysics Program, University of Montana, Missoula, Montana, USA.
Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, Montana, USA.

Qin Yu (Q)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA.

Christopher Peterson (C)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA.
Cellular, Molecular and Microbial Biology Program, University of Montana, Missoula, Montana, USA.
Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, Montana, USA.

Jessica Preece (J)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA.

Brent J Ryckman (BJ)

Division of Biological Sciences, University of Montana, Missoula, Montana, USA brent.ryckman@mso.umt.edu.
Cellular, Molecular and Microbial Biology Program, University of Montana, Missoula, Montana, USA.
Biochemistry and Biophysics Program, University of Montana, Missoula, Montana, USA.
Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, Montana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH